This site is intended for healthcare professionals

New phase III study to investigate expanded use of vericiguat in patients with chronic heart failure with reduced ejection fraction.

Read time: 1 mins
Published:16th Nov 2021
Bayer and its development partner Merck Inc., announced the start of VICTOR (VerICiguaT in adults with ChrOnic heart failure and Reduced ejection fraction), a new Phase III cardiovascular study investigating the expanded use of heart failure (HF) treatment vericiguat.

The VICTOR study will explore the efficacy of vericiguat in chronic heart failure patients and reduced ejection fraction of 40 percent or less who have not had a recent worsening HF event, a population comparable to those of several other recent heart failure studies. Based on the VICTORIA study, vericiguat was recently approved in the U.S., Japan, the EU and other countries under the brand name Verquvo. In the EU it is indicated for symptomatic chronic HF in adult patients with reduced ejection fraction who are stabilized after a recent decompensation event requiring IV therapy.

“Vericiguat is currently approved in several countries for heart failure patients who have recently experienced a worsening event. This is an area where we recognize a large unmet medical need,” said Dr. Javed Butler, the Patrick H. Lehan Chair in Cardiovascular Research, and professor and chairman of the department of medicine at the University of Mississippi Medical Center. “With VICTOR, we look forward to assessing the use of vericiguat earlier in the progression of heart failure and evaluating its potential benefit for a broader heart failure population.”

Recruitment for the VICTOR trial has begun and is expected to enroll approximately 6,000 adults with chronic HF and reduced ejection fraction of 40 percent or less who have not had a recent worsening HF event, complementary to the VICTORIA study patient population. The primary efficacy endpoint is the time to first event of cardiovascular death or hospitalization for HF (NCT05093933).

Condition: Heart Failure
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.